Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial.
about
Sunitinib in the treatment of metastatic renal cell carcinomaHeat shock protein vaccines against glioblastoma: from bench to bedsideImmunotherapy for metastatic renal cell carcinoma.Renal cell cancer: overview of the current therapeutic landscape.Increased interferon alpha receptor 2 mRNA levels is associated with renal cell carcinoma metastasisSurgical management of renal cell carcinoma: Canadian Kidney Cancer Forum Consensus.Adjuvant therapy for locally advanced renal cell cancer: a systematic review with meta-analysisRecent updates in renal cell carcinomaAdjuvant therapy for renal cell carcinoma: past, present, and futureExpression and clinical significance of cancer-testis genes in clear cell renal cell carcinoma.Targeted therapies for non-clear renal cell carcinoma.Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DThe prospects of pazopanib in advanced renal cell carcinoma.Renal cell carcinoma and the use of sorafenib.Systemic adjuvant therapies in renal cell carcinomaVaccination immunotherapy--an update.Current status of targeted therapy for advanced renal cell carcinomaNeoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma.Advances in immune-based therapies of renal cell carcinoma.Cytokine and vaccine therapy of kidney cancer.Adjuvant therapy of renal cell carcinoma: patient selection and therapeutic options.Benefit of adjuvant immunotherapy in renal cell carcinoma: A myth or a reality?Emerging drugs for renal cell carcinoma.Update on targeted therapies for clear cell renal cell carcinomaAdjuvant treatment for renal cell carcinoma.Randomized trial of adjuvant thalidomide versus observation in patients with completely resected high-risk renal cell carcinoma.Management of locally advanced renal cell carcinoma.Perioperative immunomodulation with interleukin-2 in patients with renal cell carcinoma: results of a controlled phase II trial.New drug therapies for advanced renal cell carcinoma.Age at diagnosis is a determinant factor of renal cell carcinoma-specific survival in patients treated with nephrectomy.Growing opportunities for adjuvant therapy of renal cell carcinoma: targeted drugs and vaccines.MET Inhibition in Clear Cell Renal Cell CarcinomaPazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma.Sunitinib therapy in renal cell carcinoma.Adjuvant therapy in renal cell carcinoma-past, present, and future.Adjuvant and neoadjuvant small-molecule targeted therapy in high-risk renal cell carcinoma.Recent developments in the treatment of renal cell carcinoma.Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma.Adjuvant and neoadjuvant therapy in renal cell carcinoma.Multimodality treatment paradigms for renal cell carcinoma: surgery versus targeted agents.
P2860
Q28072057-7BE2526C-2FAC-4D01-BDA6-C837D5C88D74Q28087775-0380C1E8-495C-46D7-9C42-C947E10C2A7EQ30234458-9F7C7FC0-F703-4BC6-8766-E821555B9F81Q30248354-5D7163E3-0157-40A8-A793-C10D98311C7FQ33294127-6B197700-0081-44AF-90C2-B41C0E7D9224Q33843677-DED6A6A2-1FF7-4980-8F12-FC64D9576166Q33858807-A96C8E49-3F63-4273-8D19-4DC603B89DE2Q34003369-48A2E7F2-1BBE-4443-A6D6-8D15A68981FAQ34005127-58AFF31C-EF31-4D42-9E97-6D8FEE7BE1ACQ34029148-DE972DE6-7432-4080-80B0-77BBA395FFDFQ34412479-D8ADD9BC-804D-4548-9A94-98FB83DFEAFEQ34555854-BAB52B4C-D391-495C-95FC-919B5E3BB27BQ34656393-424266CD-9BE2-4070-AB98-2ECE44AE6392Q35166782-6E8B9EC2-4A5A-45E4-8C77-F23AEADC3296Q35569322-F519961E-7ED2-467D-9E12-6527EFEE41C4Q35851700-F350350D-3CE0-4E68-88C5-F9CA36DAE97CQ35903850-9490DF91-C841-432A-9903-A8C187627C54Q35916894-424840DE-BF27-4F9B-934E-AF19D818B28EQ35987770-86680E22-B29F-49D2-993B-7385C39403C3Q35987775-B06798E7-7256-44FC-8C72-E1F15D87B8A2Q36232195-71A66D84-D2AD-48AD-89C6-F900D73E3395Q36291489-8265533C-9DBC-4D57-A462-22D201955747Q36302842-4242DC7D-3CAF-4507-922A-8590373946AAQ36369380-CE8AC668-B92D-43A2-9772-0BC684EF63D8Q36429718-F9831666-BB45-4014-B7D9-61A40FAB1762Q36491239-B910EB26-2782-4C54-B1F8-CB765238AFDEQ36555667-9D9CCB95-1086-450D-8A05-6D2723532C48Q36611853-FD8A5E46-D110-46BB-ACC8-92619BCB12C0Q36691810-73016DB1-889D-4607-9315-7B9B5BC346A1Q36995364-5C55581A-355E-4999-A09F-53983AFE854FQ37000740-6D072858-74F8-458B-8CF5-36B01AEBC66FQ37067981-F0D40A62-3723-4E38-B2A2-6A6FBEFBC703Q37071204-607E539B-D5E4-42AE-9AB0-21D612EE6949Q37088460-A0E17705-8B18-438F-8F83-C66FEB16FD21Q37153437-D89EA71C-714E-48B1-B905-5DEA6B4EBEE1Q37205794-4FEFA95D-6A6F-4DC6-A570-A550D774A55AQ37300942-DD0677DB-1B0F-4ED1-978B-1155029777E7Q37414808-2F9CB5A6-6801-4C8C-9AE3-9371B63C6DC0Q37492442-AAFF7936-DDC7-4A5E-A097-B72DF8EF3BAFQ37508012-5BDDFCB0-6D39-45B1-8C18-038B5A71DC97
P2860
Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Phase III study of interferon ...... cology Group/Intergroup trial.
@en
Phase III study of interferon ...... cology Group/Intergroup trial.
@nl
type
label
Phase III study of interferon ...... cology Group/Intergroup trial.
@en
Phase III study of interferon ...... cology Group/Intergroup trial.
@nl
prefLabel
Phase III study of interferon ...... cology Group/Intergroup trial.
@en
Phase III study of interferon ...... cology Group/Intergroup trial.
@nl
P2093
P356
P1476
Phase III study of interferon ...... cology Group/Intergroup trial.
@en
P2093
E David Crawford
Eastern Cooperative Oncology Group/Intergroup trial
Edward M Messing
J Edson Pontes
Jonathan Fleischmann
Judith Manola
Kathleen Propert
Richard Hahn
P304
P356
10.1200/JCO.2003.02.005
P407
P577
2003-04-01T00:00:00Z